Harrow Inc (HROW) USD0.001

Sell:$21.49Buy:$29.00$0.68 (3.06%)

Prices delayed by at least 15 minutes
Sell:$21.49
Buy:$29.00
Change:$0.68 (3.06%)
Prices delayed by at least 15 minutes
Sell:$21.49
Buy:$29.00
Change:$0.68 (3.06%)
Prices delayed by at least 15 minutes

Company Information

About this company

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Key people

Mark L. Baum
Chairman of the Board, Chief Executive Officer
Andrew R. Boll
Chief Financial Officer, Corporate Secretary
John P. Saharek
President and Chief Executive Officer of ImprimisRx, Chief Commercial Officer
Perry J. Sternberg
Lead Independent Director
Adrienne L. Graves
Independent Director
Lauren P. Silvernail
Independent Director
Click to see more

Key facts

  • EPIC
    HROW
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US4158581094
  • Market cap
    $868.29m
  • Employees
    315
  • Shares in issue
    35.61m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.